Synthesis of 4-Alkoxyaryl .BETA.-D-Glucopyranosides and Their Inhibitory Effects on Histamine Release from Rat Peritoneal Mast Cells Induced by Concanavalin A.
series of hydroquinone monoalkyl ethers was synthesized and evaluated for anti lipid-peroxidation activity in rat liver microsomes. 4-Hexyloxy-2,3,6-trimethylphenol (9), having a low redox potential, as well as ascorbic acid exhibited the strongest anti lipid-peroxidation activity (IC50 = 4.2 x 10(-7) M). Structure-activity relationship studies demonstrated that the inhibitory effect of hydroquinone monoalkyl
合成了一系列氢醌单烷基醚,并评估了其在大鼠肝微粒体中的抗脂质过氧化活性。氧化还原电位低的4-己氧基-2,3,6-三甲基苯酚(9)以及抗坏血酸表现出最强的抗脂质过氧化活性(IC50 = 4.2 x 10(-7)M)。结构活性关系研究表明,对苯二酚单烷基醚对脂质过氧化的抑制作用通过获得最佳疏水性而增加,而由于疏水性不足或过度而降低。
Synthesis of 4-Alkoxyaryl .BETA.-D-Glucopyranosides and Their Inhibitory Effects on Histamine Release from Rat Peritoneal Mast Cells Induced by Concanavalin A.
The inhibitory effects of newly synthesized 4-alkoxyaryl β-D-glucopyranosides on histamine release from rat peritoneal mast cells induced by concanavalin A were examined. A plot of hydrophobicity (k') against inhibitory activity of the compounds showed a distinct maximum, and 4-decyloxy-2, 3, 6-trimethylphenyl β-D-glucopyranoside was the most potent inhibitor among the tested compounds.
A compound is prepared based on Formula 1:
wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6 or alkoxycarbonyl group with a carbon number of 2 to 6. A curative drug for neurodegenerative diseases can be prepared principally from the compound or a hydroquinone derivative consisting of a cyclodextrin inclusion compound thereof. The curative drug for neurodegenerative diseases has a safe and beneficial effect of inhibiting nerve cell disorder due to oxidative stress, thereby to stop progression of symptoms. The diseases include Alzheimer's and Parkinson's disease.
The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula:
wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6, or alkoxycarbonyl group with a carbon number of 2 to 6.
CHRONIC RESPIRATORY DISEASE THERAPEUTIC AGENT AND CARDIAC FIBRILLATION SUPPRESSING COMPOSITION
申请人:NIPPON HYPOX LABORATORIES INCORPORATED
公开号:EP3287128A1
公开(公告)日:2018-02-28
A novel agent which is effective in the prevention or treatment of a chronic respiratory disease such as COPD, interstitial pneumonia and asthma is provided. The therapeutic agent for a chronic respiratory disease comprises, as an active ingredient, a hydroquinone derivative represented by general formula (1) wherein R1 represents an alkyl group having 4 to 8 carbon atoms, and R2 represents a hydrogen atom, an alkylcarbonyl group having 2 to 6 carbon atoms or an alkoxycarbonyl group having 2 to 6 carbon atoms.